A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
← catalyst calendarNCT07481981 · readout in 862 d
Sponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
344estimated
Sites
3
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-21 | actual | When the study began enrolling |
| Primary completion | 2028-12-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Arterial Hypertension
Interventions
- Drug: Treprostinil Palmitil Inhalation Powder — also filed as INS1009
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in 6-Minute Walk Distance (6MWD) Measured at 1 to 3 Hours Post-Dose From Baseline at Week 24
measured Baseline, Week 24
Permalink · INSM's whole pipeline · Catalyst calendar · Every registered study · What changed